Skip to content

Inovio Pharmaceuticals, Inc.

INO· NasdaqCore metricsCIK 1055726

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -1.01%
Market cap
$274.40M
187.31M shares
Filings
1,026
$298.90K
Q3 2026−70.0% FY25 yoy
-$49.20M
Q3 2026N/M FY25 yoy
-$19.52M
Q3 2026N/M FY25 yoy
-$54.91M
Q3 2026derivedN/M FY25 yoy
-$0.50
Q3 2026N/M FY25 yoy
$46.96M
Q3 2026−32.7% FY25 yoy
$274.40M
—
918.0×
—
-27.12%
—

Twelve months to Sep 30, 2026 · derived

Price

$1.4726.75%$0.53past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$65.34KFY 2025
$42.22M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$65,343reported
FY 20242024-12-31$217,756reported
FY 20232023-12-31$832,010reported
FY 20222022-12-31$10,262,268reported
FY 20212021-12-31$1,774,758reported
FY 20202020-12-31$7,411,220reported
FY 20192019-12-31$4,111,930reported
FY 20182018-12-31$30,481,897reported
FY 20172017-12-31$42,220,086reported
FY 20162016-12-31$35,368,361reported
FY 20152015-12-31$40,572,111reported
FY 20142014-12-31$10,456,766reported

Segments

Products
Revenue by Products, FY2018 to FY2021FY2018Revenue under collaborative research and development arrangements · FY2018 · $29.86MOther revenue · FY2018 · $171.59KRevenue under collaborative research and development arrangements from affiliated entities · FY2018 · $449.52KFY2019Revenue under collaborative research and development arrangements · FY2019 · $3.64MOther revenue · FY2019 · $237.54KRevenue under collaborative research and development arrangements from affiliated entities · FY2019 · $235.65KOther revenue from affiliated entities · FY2019 · $1.80KFY2020Revenue under collaborative research and development arrangements · FY2020 · $5.17MOther revenue · FY2020 · $786.90KRevenue under collaborative research and development arrangements from affiliated entities · FY2020 · $1.45MFY2021Revenue under collaborative research and development arrangements · FY2021 · $902.26KOther revenue · FY2021 · $627.19KRevenue under collaborative research and development arrangements from affiliated entities · FY2021 · $245.31K
LineFY2021ShareChange
Revenue under collaborative research and development arrangements$902.26K51%−82.6%
Other revenue$627.19K35%−20.3%
Revenue under collaborative research and development arrangements from affiliated entities$245.31K14%−83.1%
Other revenue from affiliated entities$0.00——
Total$1.77M

From the 10-K filed Mar 1, 2022INO

Pharmaceutical preparations

Inovio Pharmaceuticals, Inc. is the 245th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR